Basics Kyverna Therapeutics, Inc. Common Stock IPO Date: February 9, 2024 Sector: Healthcare Industry: Biotech Market Cap: $170.39M Activated in VL: True Average Daily Range Avg Daily Range: $0.33 | 4.33% Avg Daily Range (30 D): $0.13 | 3.61% Avg Daily Range (90 D): $0.15 | 4.90% Institutional Daily Volume Avg Daily Volume: .35M Avg Daily Volume (30 D): .23M Avg Daily Volume (90 D): .33M Trade Size Avg Trade Size (Sh.): 98 Avg Trade Size (Sh.) (30 D): 118 Avg Trade Size (Sh.) (90 D): 125 Institutional Trades Total Inst.Trades: 111 Avg Inst. Trade: $1.88M Avg Inst. Trade (30 D): $2.74M Avg Inst. Trade (90 D): $2.74M Avg Inst. Trade Volume: .16M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.79M Avg Closing Trade (30 D): $6.42M Avg Closing Trade (90 D): $6.42M Avg Closing Volume: 272.03K     News Aug 28, 2025 @ 12:00 PM Kyverna Therapeutics Highlights Neuroimmunology CA... Source: Kyverna Therapeutics Mar 18, 2025 @ 8:48 PM Notice to Long-Term Shareholders of Archer-Daniels... Source: Grabar Law Office Mar 13, 2025 @ 10:21 PM Long-Term Shareholder Notice: Fluence Energy, Inc.... Source: Grabar Law Office Mar 5, 2025 @ 6:00 PM CAR T-cell Therapy Clinical Trial Pipeline Experie... Source: Delveinsight Feb 6, 2025 @ 6:51 PM Investors in Kyverna Therapeutics, Inc. Should Con... Source: The Gross Law Firm Financials   TTM Q2 2025 Q1 2025 Basic EPS $-3.69 $-.97 $-1.03 Diluted EPS $-3.69 $-.97 $-1.03 Revenue $ M $ M $ M Gross Profit $ $ $ Net Income / Loss $ -158.7M $ -42.08M $ -44.64M Operating Income / Loss $ -171.63M $ -44.41M $ -47.41M Cost of Revenue $ $ $ Net Cash Flow $ -78.2M $ -3.43M $ -39.75M PE Ratio